Marco Siddi
Oral agents in multiple sclerosis
LOREFICE, LORENA;FENU, GIUSEPPE;FRAU, JESSICA;COGHE, GIANCARLO;MARROSU, MARIA GIOVANNA;COCCO, ELEONORA
2015-01-01
Abstract
Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous system. Disease-modifying drugs licensed for MS treatment have been developed to reduce relapse rates and halt disease progression. The majority of current MS drugs involve regular, parenteral administration, affecting long-term adherence and thus reducing treatment efficacy. Over the last two decades great progress has been made towards developing new MS therapies with different modes of action and biologic effects. In particular, oral drugs have generated much interest because of their convenience and positive impact on medication adherence. Fingolimod was the first launched oral treatment for relapsing-remitting MS; recently, Teriflunomide and Dimethyl fumarate have also been approved as oral disease-modifying agents. In this review, we summarize and discuss the history, pharmacodynamics, efficacy, and safety of oral agents that have been approved or are under development for the selective treatment of MS.File | Dimensione | Formato | |
---|---|---|---|
005AA.pdf Solo gestori archivio
Tipologia: versione editoriale
Dimensione 258.94 kB
Formato Adobe PDF
|
258.94 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.